During the first quarter of 2016, Novartis reported $17 million in sales of sacubitril/valsartan (Entresto), which was short of analyst expectations.

Lobbyist and attorney Jim Davidson told attendees at an advertising conference to stick up for pharmaceutical advertising, STAT reports.

A retrospective registry analysis in Sweden found patients with nonvavular atrial fibrillation who were treated with warfarin had an annual incidence of 2.19 percent for all-cause mortality and 0.44 percent for intracranial bleeding.

A cardiologist from Florida who made tens of millions from Medicare declared for declared for bankruptcy, the Wall Street Journal reports. 

Researchers in Australia have developed a predictive score for the likelihood of 30-day readmission or death from heart failure that includes determinants such as echocardiography, mental health, cognitive function and individual socioeconomic status that were not incorporated in previous models.

Sales of two cholesterol-lowering medications that the FDA approved last summer have fell far short of expectations, the Associated Press reports. 

Cardiologists and other healthcare professionals are inundated with more information than ever, are facing changes in reimbursement and practice patterns and are undertaking more administrative/nonclinical duties.

A post-hoc analysis of a randomized study found that intermediate-risk participants who had a family history of coronary heart disease and received a genetic risk score were more likely to take statins.